Study S000011

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)

ClinicalTrials.gov record

Registration

Registration: NCT02100475
Acronym: DUAL™
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 31
Start: 2014-04
Primary completion: 2015-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:insulin degludec/liraglutide; DRUG:insulin aspart
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2013-002878-47; OTHER:U1111-1145-0183

Registered primary outcomes

Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.